Chelators for 68Ga radiopharmaceuticals
Seelam Sudhakara Reddy, 이윤상, 정재민,
소속 상세정보
( Seelam Sudhakara Reddy )
Seoul National University College of Medicine Department of Nuclear Medicine
이윤상 ( Lee Yun-Sang )
Seoul National University College of Medicine Department of Nuclear Medicine
정재민 ( Jeong Jae-Min )
Seoul National University College of Medicine Department of Nuclear Medicine
Abstract
68Ga is a promising radionuclide for positron emission tomography (PET). It is a generator-produced (68Ge/68Ga-generator) radionuclide with a half-life of 68 min. The employment of 68Ga for basic research and clinical applications is growing exponentially. Bifunctional chelators (BFCs) that can be efficiently radiolabeled with 68Ga to yield complexes with good in vivo stability are needed. Given the practical advantages of 68Ga in PET applications, gallium complexes are gaining increasing attention in biomedical imaging. However, new 68Ga-labeled radiopharmaceuticals that can replace 18F-labeled agents like [18F]fluorodeoxyglucose (FDG) are needed. The majority of 68Ga-labeled derivatives currently in use consist of peptide agents, but the development of other agents, such as amino acid or nitroimidazole derivatives and glycosylated human serum albumin, is being actively pursued in many laboratories. Thus, the availability of new 68Ga-labeled radiopharmaceuticals with high impact is expected in the near future. Here, we present an overview of the different new classes of chelators for application in molecular imaging using 68Ga PET.
키워드
68Ga; Radiochemistry; Coordination chemistry; Bifunctional chelators; Cyclic and acyclic chelators
원문 및 링크아웃 정보
등재저널 정보